The Parkinson's disease therapy developer completed a series A round featuring QB3-aligned Mission Bay Capital.
Nitrome Biosciences, a US-based developer of treatments for age-related disorders, has secured $38m in a series A round backed by Mission Bay Capital, the VC arm of University of California-aligned commercialisation office California Institute for Quantitative Biosciences.
AbbVie Ventures, the corporate venturing arm of pharmaceutical firm AbbVie, and VC firm Sofinnova Partners co-led the round, which also included Alexandria Venture Investments, the VC arm of life sciences real estate investment trust Alexandria Real Estate Equities, and Dementia Discovery…
